Spinal cord compression OR rapid PSA doubling time (<3 months) OR new visceral metastases...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-PROSTATE-TRANSFORMATION-PROGRESSION |
|---|---|
| Type | Red flag |
| Status | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Red Flag Origin
| Definition | Spinal cord compression OR rapid PSA doubling time (<3 months) OR new visceral metastases — emergency or aggressive-progression flag requiring urgent intervention or treatment intensification. |
|---|---|
| Clinical direction | hold |
| Category | transformation-progression |
Trigger Logic
{
"any_of": [
{
"finding": "spinal_cord_compression",
"value": true
},
{
"comparator": "<",
"finding": "psa_doubling_time_months",
"threshold": 3
},
{
"finding": "new_visceral_metastases",
"value": true
}
],
"type": "composite_clinical"
}
Notes
Spinal cord compression: emergent neurosurgical / RT consult AND immediate testosterone suppression (degarelix preferred for speed vs LHRH agonists). PSA doubling time <3 months in nmCRPC: criterion for ARPI initiation per NCCN. Visceral mets in mCRPC: docetaxel or cabazitaxel preferred over additional ARPI (cross-resistance). Direction `hold` reflects priority — emergent care precedes scheduled systemic therapy decisions.
Used By
Indications
IND-PROSTATE-MCRPC-1L-ARPI- IND-PROSTATE-MCRPC-1L-ARPIIND-PROSTATE-MCRPC-1L-PARPI- IND-PROSTATE-MCRPC-1L-PARPIIND-PROSTATE-MCRPC-2L-CABAZITAXEL- IND-PROSTATE-MCRPC-2L-CABAZITAXELIND-PROSTATE-MCRPC-2L-DOCETAXEL- IND-PROSTATE-MCRPC-2L-DOCETAXELIND-PROSTATE-MCRPC-2L-LU-PSMA- IND-PROSTATE-MCRPC-2L-LU-PSMAIND-PROSTATE-MCRPC-2L-RADIUM223- IND-PROSTATE-MCRPC-2L-RADIUM223IND-PROSTATE-MHSPC-1L-ARPI-DOUBLET- IND-PROSTATE-MHSPC-1L-ARPI-DOUBLETIND-PROSTATE-MHSPC-1L-TRIPLET- IND-PROSTATE-MHSPC-1L-TRIPLET